Zhang et al. evaluated PET-CT PSMA in patients with suspected prostate cancer before biopsy, reporting a PPV of 89.19% and an NPV of 85.71%, with an area under the curve (AUC) of 0.867 [8]. This evidence concerns the gene FOLH1 and prostate carcinoma.